Edmond Lay

Cooley advised Jiangsu Hengrui Pharmaceuticals, one of the largest pharmaceutical companies in China, on its licensing of global rights (excluding Greater China) for the development, production and commercialization of three of its proprietary glucagon-like peptide-1 (GLP-1) drugs to Hercules CM Newco, a newly established Delaware company.

Cooley advised Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, on its concurrent $240 million private placement financing and definitive agreement with Janssen Pharmaceuticals, a Johnson & Johnson Company, to reacquire the exclusive global development and commercial rights to CD388.

Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its $147.9 million initial public offering.

Cooley advised Alto Neuroscience, a company pioneering precision psychiatry by developing targeted medicines designed to help patients get better faster, on its oversubscribed $45 million Series C financing round.

Cooley advised Tentarix Biotherapeutics and three of its subsidiaries on three multiyear collaborations with Gilead Sciences.